Cohance Life
Cohance Life Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra). Growth in H2 FY27 is expected to be better than H1 due to new molecule additions and reload orders, particularly in Pharma CDMO and API+ segments.
From Cohance Life's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra).
- Pharma CDMO business projected to have strong sequential Q2FY27 growth compared to Q1FY27, with long-term growth driven by 7 product filings in FY27 (Gunjan Singh, Umang Vohra).
- API+ segment seen as a sustainable, growing business with potential to double over 3-4 years, driven by CNS focus and innovator relationships (Gunjan Singh).
- ADC business currently cost-heavy but expected to improve with pipeline development and revenue growth (Umang Vohra).
2 more points from Cohance Life's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Cohance Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure during the quarter was approximately INR 598 million, focused on investing in capabilities required for future growth.
- Investment includes a commercial flow reactor at the Jaggayyapet site, expected to be ready by next quarter.
- Completed debottlenecking initiatives for several products and commissioned a new effluent treatment facility at Ankleshwar to enhance capacity and compliance.
- Ongoing remediation and operational stabilization efforts at the Nacharam facility, supporting CAPA implementation and full normalization.
2 more points from Cohance Life's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Cohance Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company experienced shipment timing and customer approval delays causing Q1FY27 revenue shortfall.
- A commercial restocking order has been secured, with deliveries scheduled across Q2FY27 and Q3FY27.
- The late-stage opportunity funnel has expanded, supporting growth momentum in the second half of FY27.
- The Pharma CDMO segment received meaningful delivery visibility for Q4 FY27 and FY28 due to restocking orders.
- RFQ pipeline is strengthening, backed by numerous Phase 3 KSM commercial supply inquiries from large pharma companies and Western CDMOs.
- Multiple customer programs have progressed through qualification stages, including two Japanese innovators' first qualifications scheduled in FY27.
2 more points from Cohance Life's call on order book
Create a free account to keep reading this call
Cohance Life — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹619 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Cohance Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Cohance Life and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Cohance Life Q1 FY27 results?
H2 FY27 expected to show growth over the previous year with new molecules and reload/older molecules contributing (Umang Vohra). Growth in H2 FY27 is expected to be better than H1 due to new molecule additions and reload orders, particularly in Pharma CDMO and API+ segments.
What is Cohance Life share price analysis?
Cohance Life currently shows a below-average growth signal. The stock trades at a P/E of 164.9 with a market cap of ₹17,754 Cr. Investors should review the full earnings analysis for detailed insights.
Is Cohance Life planning capital expenditure?
Capital expenditure during the quarter was approximately INR 598 million, focused on investing in capabilities required for future growth.
Keep Cohance Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.